Demo
KRYS Nasdaq· Krystal Biotech Inc.
FundamentalsNews digest Peer analysis
Login
KRYS Nasdaq· Krystal Biotech Inc.
Earnings report Q4 2023

Krystal Biotech Reports Strong Revenue Growth in Latest Quarter

Segments of revenue

In the latest quarter, Krystal Biotech reported total product revenue of $50.7 million. This represents a significant increase compared to the previous quarters, where no product revenue was generated. The company's product revenue is derived from the sale of its biotechnology products.

Strengths

Krystal Biotech demonstrated strong revenue growth in the latest quarter, primarily driven by the significant increase in product revenue. This growth can be attributed to the successful commercialization of the company's biotechnology products. The management has focused on expanding its product portfolio and effectively marketing its offerings, resulting in increased sales. The positive reception of Krystal Biotech's products in the market has contributed to its revenue growth.

Challenges

While Krystal Biotech achieved impressive revenue growth in the latest quarter, it is important to note that the company has incurred substantial expenses. The cost of goods sold, research and development expenses, and selling, general, and administrative expenses have all increased compared to the previous quarters. These expenses pose a challenge to the company's profitability and highlight the need for effective cost management strategies.

Noteworthy

One noteworthy aspect of Krystal Biotech's performance in the latest quarter is the gain from the sale of a priority review voucher, amounting to $100 million. This gain significantly contributed to the company's overall income before taxes. Additionally, the company reported a comprehensive income of $12.3 million, which includes unrealized income on available-for-sale securities and other investments.

Summary

Krystal Biotech's latest quarter performance showcases strong revenue growth, primarily driven by the significant increase in product revenue. The successful commercialization of the company's biotechnology products and effective marketing strategies have contributed to this growth. However, the company faces challenges in managing its expenses, which have increased compared to previous quarters. The gain from the sale of a priority review voucher and comprehensive income further highlight the company's performance. Overall, Krystal Biotech's revenue growth demonstrates its ability to capitalize on market opportunities and deliver positive financial results.

Source documents

Form 10-K  filed on Feb 26, 2024
26 pages scanned

Reference data

Company financials Q4 revenue 42.1M
Analyst estimates Q4 EPS missed by -242.59%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.